The growing evidence regarding HSP90 interactions with JAK/STAT signaling, both in vitro [41] and in vivo [40], supports the idea that HSP90 inhibition might be of therapeutic interest in JAK/STAT dysregulated diseases such as MPN [42]. This evidence concerns the gene SOAT1 and myeloproliferative disorder.